Neuro-Oncology Reviews
Volume
27 Number 35
20 December 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 35, 20 December
Drappatz J, Mantica M.
Treatment
strategies and innovation for recurrent high-grade glioma.
J
Neurooncol. 2025 Dec 11;176(1):118. doi:
10.1007/s11060-025-05323-3. PMID:
41381983. Review˰
ˍ
Drapkin AJ.
On the question of
prognosis in cystic gliomas.
World
Neurosurg. 2025 Dec 11:124714. doi:
10.1016/j.wneu.2025.124714. PMID:
41390081. Perspective. ˍ
Karsonovich T, Gasalberti DP, Rayi A.
Low-Grade
Gliomas.
StatPearls
Publishing, Treasure Island (FL), 2025 Dec 13. PMID:
32809503. Bookshelf
ID: NBK560668. Book. ˍ
McKerill E, Tan JK, Rao CK, Linares CA, Banerjee S, Rabbani RD,
Adeleke S, Ghose A, Boussios S.
Efficacy
of ketogenic metabolic therapy as an adjuvant to the current
standard of care in the treatment of glioblastoma: A systematic
review of clinical trials.
Med
Oncol. 2025 Dec 11;43(1):49. doi:
10.1007/s12032-025-03165-7. PMID:
41379280. Review. ˍ
Ehret F, Rogers CL, Fontanesi J, Wilson GD, Chitti BS, Starner J,
Sidiqi B, Goenka A, Schulder M, Bruynzeel AME, Verhoeff JJC,
MacDonagh AC, Park HI, Shih HA, Kleinberg L.
Radiation
Therapy for Non-Malignant Central Nervous System Tumors,
Disorders, and Illnesses - Current Applications and Future
Directions.
Semin
Radiat Oncol. 2025 Dec 12;36:77-94. doi:
10.1016/j.semradonc.2025.08.005. PMID:
41391900. Review. ˍ
Scagliotti E, Capetti B, Conti L, Fiore G, Fanizzi C, Bertani G,
Pravettoni G, Locatelli M.
Effects of
proton therapy on cognition in adults with brain tumors: a
systematic review.
J
Neurooncol. 2025 Dec 12;176(1):121. doi:
10.1007/s11060-025-05371-9. PMID:
41385035. Review˰
ˍ
Jia L, Chen Y, Li H, Zhao K, Ge S, Wang C, Zhao J, Li F, Zhang L,
Yao A.
The glymphatic system in
neurodegenerative diseases and brain tumors: mechanistic insights,
biomarker advances, and therapeutic opportunities.
Acta
Neuropathol Commun. 2025 Dec 13. doi:
10.1186/s40478-025-02203-9. PMID:
41390476. Review. ˍ
Love CA, Figg JW, Engelbart M, West I, Flores C.
Radial
glial cells and glioblastoma: how developmental neurobiology can
inform our understanding of brain cancer initiation, treatment
resistance, and resilience.
Transl
Oncol. 2025 Dec 13;64:102645. doi:
10.1016/j.tranon.2025.102645. PMID:
41391380. Review. ˍ
Boffelli L, Fimiani C, Núñez NG, Kienzler JC.
Synergy of radiotherapy, focused
ultrasound, and immunotherapy in the treatment of brain
metastases.
J
Neurooncol. 2025 Dec 15;176(1):124. doi:
10.1007/s11060-025-05379-1. PMID:
41396538. Review. ˍ
Sadhasivam S, Velpula S, Prasanna L, Arora RK, Menon G, Nair SN.
Impact of awake mapping on extent of
resection and neurological outcomes of Low-grade gliomas: a
systematic review and Meta-analysis.
Neurosurg
Rev. 2025 Dec 16;49(1):74. doi:
10.1007/s10143-025-03998-w. PMID:
41398134. Review; Meta-analysis˰
ˍ
Pang C, Wang Y.
The Immunosuppressive
Microenvironment of Glioblastoma: Mechanisms, Clinical Challenges
and Future Directions.
Immunology.
2025 Dec 19. doi:
10.1111/imm.70087. PMID:
41414954. Review. ˍ
Galldiks N.
Influence of
corticosteroids on contrast enhancement in patients with untreated
glioblastoma.
Neuro
Oncol. 2025 Sep 11:noaf207. doi:
10.1093/neuonc/noaf207. PMID:
41384841. Editorial˰
ˍ
Amjad A, Ali MR, Khalid M, Segawa F.
Liquid
biopsies for early detection of gliomas: are we near a
breakthrough?
Ann
Med Surg (Lond). 2025 Sep 30;87(12):7862-7863. doi:
10.1097/MS9.0000000000003987. PMID:
41377322. Editorial.
ˍ
Zafar S, Furqan M, Binte Rahim S, Haider MU.
Dordaviprone
in H3K27M-mutant diffuse midline glioma: an editorial on emerging
targeted therapy.
Ann
Med Surg (Lond). 2025 Oct 13;87(12):7886-7888. doi:
10.1097/MS9.0000000000004079. PMID:
41377309. Editorial.
ˍ
Tague C, Ekouo J, Makeda D, Yokolo H, Onesime J, Banga S,
Kashafali A, Taj J, Akilimali A.
Toward
cancer immunoprevention: what are the prospects for therapeutic
vaccines?
Ann
Med Surg (Lond). 2025 Oct 30;87(12):7926-7927. doi:
10.1097/MS9.0000000000004234. PMID:
41377366. Editorial.
ˍ
Bria J, Filardo A, Di Vito A, Della Torre A, Lavano A, Coscarella
I, Chiarella E, Procopio E, Egiziano MT, Longo P, La Torre
D.
Recurrent Limitations of CAR-T
Therapy in Gliomas: Evidence from Preclinical and Phase I Clinical
Studies.
Int
J Mol Sci. 2025 Nov 26;26(23):11435. doi:
10.3390/ijms262311435. PMID:
41373591. Review. ˍ
Fanuzzi M, Zheng S, Horbinski CM, Shaaban MA, Congivaram H, Du R,
Tripathi S, Hurley L, Kumthekar P, Ahmed A, Brat DJ, Lesniak MS,
Heimberger AB.
Targeting Survivin: Now
I Become Death, the Destroyer of Cells.
Int
J Mol Sci. 2025 Nov 26;26(23):11417. doi:
10.3390/ijms262311417. PMID:
41373575. Review. ˍ
Stathopoulos A, Glorieux P, Rokas EM, Savelkoul HFJ.
Combined
Tumor Cell and Lysate-Based Vaccines for Immunotherapy of Primary
and Recurrent Glioblastoma (GBM).
Cancers
(Basel). 2025 Nov 26;17(23):3772. doi:
10.3390/cancers17233772. PMID:
41374974. Review. ˍ
Zoi V, Galani V, Sioka C, Alexiou GA, Kyritsis AP.
Immunotherapy
for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors.
Cancers
(Basel). 2025 Nov 26;17(23):3777. doi:
10.3390/cancers17233777. PMID:
41374979. Review. ˍ
Tleubergenov MA, Zhamoldin DK, Baymukhanov DS, Omarova AS,
Ryskeldiyev NA, Doskaliyev A, Ukybassova TM, Akshulakov S.
Brain
Tumors in Pregnancy: A Review of Pathophysiology, Clinical
Management, and Ethical Dilemmas.
Cancers
(Basel). 2025 Nov 30;17(23):3854. doi:
10.3390/cancers17233854. PMID:
41375054. Review. ˍ
Bao Y, Chen Z, Su Y, Guo T, Du H, Jia X.
From
neuroinflammation to gliomagenesis: immune drivers of malignant
transformation in the CNS.
Front
Immunol. 2025 Dec 1;16:1682030. doi:
10.3389/fimmu.2025.1682030. PMID:
41403936. Review. ˍ
Tang E, Chen JY.
Shaping the
glioblastoma microenvironment to enhance CAR-NK immunotherapy.
Front
Immunol. 2025 Dec 1;16:1681966. doi:
10.3389/fimmu.2025.1681966. PMID:
41403931. Review. ˍ
Duran G, Pichardo-Rojas D, Ali AH, Passias P, Downes A, Ray WZ,
Zipfel GJ, Shakir HJ, Bauer A, Jea A, Dunn IF, Zuccato JA, Graffeo
CS, Janjua MB.
Comparing Isocitrate
Dehydrogenase Inhibitors with Procarbazine, Lomustine, and
Vincristine Chemotherapy for Oligodendrogliomas.
Cancers
(Basel). 2025 Dec 4;17(23):3880. doi:
10.3390/cancers17233880. PMID:
41375081. Review. ˍ
Bayona C, Ranđelović T, Ochoa I.
Tumor
Microenvironment in Glioblastoma: The Central Role of the
Hypoxic-Necrotic Core.
Cancer
Lett. 2025 Dec 9:218216. doi:
10.1016/j.canlet.2025.218216. PMID:
41380902. Review. ˍ
Preetam S, Rabbee MF, Mishra R, Thapliyal S, Deshwal R, Rustagi S,
Dashmana A, Govindarajan RK, Malik S.
Targeting
brain tumours with precision: advances in magnetic nanoparticle
therapy.
Nanoscale
Adv. 2025 Dec 9. doi:
10.1039/d5na01046b. PMID:
41404476. Review. ˍ
Wang J, Zhang Y, Kang Z, Li S, Zhang R, Huang M, Wang C, Fan Y,
Liu X, Chen Y, Han T, Wang Y, Li W.
Bidirectional
Causal Effect Between Gut Microbiota and Glioma Risk: A Systematic
Review-Based Mendelian Randomization and Immune-Mediated Effect
Analysis.
Cancer
Innov. 2025 Dec 9;4(6):e70039. doi:
10.1002/cai2.70039. PMID:
41384027. Review. ˍ
Sarfraz Z, Ranjan T, Mustafayev FNA, Jaramillo M, Odia Y, Venur
VA, Ahluwalia MS.
Emerging therapies
for glioblastoma.
J
Neurooncol. 2025 Dec 10;176(1):116. doi:
10.1007/s11060-025-05248-x. PMID:
41372729. Review˰ ˍ
Zam A, Rouatbi N, Walters AA, Al-Jamal KT.
Overcoming
barriers and shaping the future: Challenges and innovations in
nucleic acid therapies for Glioblastoma.
Adv
Drug Deliv Rev. 2025 Dec 10;229:115759. doi:
10.1016/j.addr.2025.115759. PMID:
41386501. Review. ˍ